- Home
- FULC vs ENTA Comparison
FULC vs ENTA Comparison
Compare FULC & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- ENTA
- Stock Information
- Founded
- FULC 2015
- ENTA 1995
- Country
- FULC United States
- ENTA United States
- Employees
- FULC N/A
- ENTA N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- FULC Health Care
- ENTA Health Care
- Exchange
- FULC Nasdaq
- ENTA Nasdaq
- Market Cap
- FULC 221.5M
- ENTA 245.4M
- IPO Year
- FULC 2019
- ENTA 2013
- Fundamental
- Price
- FULC $3.64
- ENTA $10.78
- Analyst Decision
- FULC Hold
- ENTA Buy
- Analyst Count
- FULC 10
- ENTA 4
- Target Price
- FULC $7.44
- ENTA $20.00
- AVG Volume (30 Days)
- FULC 676.6K
- ENTA 112.1K
- Earning Date
- FULC 11-13-2024
- ENTA 11-25-2024
- Dividend Yield
- FULC N/A
- ENTA N/A
- EPS Growth
- FULC N/A
- ENTA N/A
- EPS
- FULC N/A
- ENTA N/A
- Revenue
- FULC $81,630,000.00
- ENTA $71,960,000.00
- Revenue This Year
- FULC $2,821.96
- ENTA N/A
- Revenue Next Year
- FULC N/A
- ENTA $5.14
- P/E Ratio
- FULC N/A
- ENTA N/A
- Revenue Growth
- FULC 2582.55
- ENTA N/A
- 52 Week Low
- FULC $2.87
- ENTA $8.11
- 52 Week High
- FULC $13.70
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- FULC 50.49
- ENTA 38.62
- Support Level
- FULC $3.38
- ENTA $10.70
- Resistance Level
- FULC $3.63
- ENTA $11.83
- Average True Range (ATR)
- FULC 0.16
- ENTA 0.48
- MACD
- FULC 0.12
- ENTA -0.10
- Stochastic Oscillator
- FULC 87.18
- ENTA 2.60
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.